BRAF V600E in HCC is exceptional (<1%). Tissue-agnostic dabrafenib + trametinib could be...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-HCC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-HCC |
| Sources | SRC-AASLD-HCC-2023 SRC-CIVIC SRC-NCCN-HCC-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-HCC |
| ESCAT tier | IIIB |
| Evidence summary | BRAF V600E in HCC is exceptional (<1%). Tissue-agnostic dabrafenib + trametinib could be considered after standard lines. |
Notes
ESCAT IIIB.
Used By
No reverse references found in the YAML corpus.